Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA.

Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16.

PMID:
29549161
2.

Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate.

Nielsen UB, Bruhn LV, Ellingsen T, Stengaard-Pedersen K, Hornung N.

Scand J Clin Lab Invest. 2018 Feb - Apr;78(1-2):62-67. doi: 10.1080/00365513.2017.1413591. Epub 2017 Dec 11.

PMID:
29228799
3.

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).

Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, Pace E, Harms B, Kim J, Kearns J, Fulgham A, Burenkova O, Grantcharova V, Yarar D, Paragas V, Fitzgerald J, Wainszelbaum M, West K, Mathews S, Nering R, Adiwijaya B, Garcia G, Kubasek B, Moyo V, Czibere A, Nielsen UB, MacBeath G.

NPJ Syst Biol Appl. 2017 Jan 5;3:16034. doi: 10.1038/npjsba.2016.34. eCollection 2017. Review.

4.

HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.

Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF.

PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr.

5.

Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers.

Kirouac DC, Lahdenranta J, Du J, Yarar D, Onsum MD, Nielsen UB, McDonagh CF.

CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00019. doi: 10.1002/psp4.19. Epub 2015 Mar 4.

6.

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).

Geretti E, Leonard SC, Dumont N, Lee H, Zheng J, De Souza R, Gaddy DF, Espelin CW, Jaffray DA, Moyo V, Nielsen UB, Wickham TJ, Hendriks BS.

Mol Cancer Ther. 2015 Sep;14(9):2060-71. doi: 10.1158/1535-7163.MCT-15-0314. Epub 2015 Jul 10.

7.

Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.

Yarar D, Lahdenranta J, Kubasek W, Nielsen UB, MacBeath G.

Mol Cancer Ther. 2015 Sep;14(9):2072-80. doi: 10.1158/1535-7163.MCT-15-0075. Epub 2015 Jun 26.

8.

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.

Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, Fitzgerald JB, Nielsen UB, Wolf BB.

Mol Cancer Ther. 2015 Jul;14(7):1625-36. doi: 10.1158/1535-7163.MCT-14-0772. Epub 2015 Apr 24.

9.

Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.

Zhang K, Geddie ML, Kohli N, Kornaga T, Kirpotin DB, Jiao Y, Rennard R, Drummond DC, Nielsen UB, Xu L, Lugovskoy AA.

MAbs. 2015;7(1):42-52. doi: 10.4161/19420862.2014.985933.

10.

Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.

Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, Nielsen UB, Fitzgerald JB.

Cancer Res. 2014 Dec 1;74(23):7003-13. doi: 10.1158/0008-5472.CAN-14-0572. Epub 2014 Oct 1.

11.

Insulin-like growth factor promotes cardiac lineage induction in vitro by selective expansion of early mesoderm.

Engels MC, Rajarajan K, Feistritzer R, Sharma A, Nielsen UB, Schalij MJ, de Vries AA, Pijnappels DA, Wu SM.

Stem Cells. 2014 Jun;32(6):1493-502. doi: 10.1002/stem.1660.

12.

MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.

Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, Razlog M, Jiao Y, Harms BD, Olivier KJ Jr, Schoeberl B, Nielsen UB, Lugovskoy AA.

Mol Cancer Ther. 2014 Feb;13(2):410-25. doi: 10.1158/1535-7163.MCT-13-0255. Epub 2013 Nov 26.

13.

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.

Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E, McDonagh CF, Nielsen UB, Onsum MD.

Sci Signal. 2013 Aug 13;6(288):ra68. doi: 10.1126/scisignal.2004008. Erratum in: Sci Signal. 2014 Sep 30;7(345):er5.

PMID:
23943608
14.

HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.

Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, Noble CO, L├╝cker PB, Zandstra PW, Drummond DC, Olivier KJ Jr, Nielsen UB, Niyikiza C, Agresta SV, Wickham TJ.

Toxicol Appl Pharmacol. 2012 Jul 1;262(1):1-10. doi: 10.1016/j.taap.2012.04.008. Epub 2012 Apr 21.

PMID:
22676972
15.

Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD.

Mol Cancer Ther. 2012 Jul;11(7):1467-76. doi: 10.1158/1535-7163.MCT-11-1038. Epub 2012 May 7.

16.

Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB.

Mol Cancer Ther. 2012 Mar;11(3):582-93. doi: 10.1158/1535-7163.MCT-11-0820. Epub 2012 Jan 16.

17.

Building and characterizing antibody-targeted lipidic nanotherapeutics.

Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC.

Methods Enzymol. 2012;502:139-66. doi: 10.1016/B978-0-12-416039-2.00007-0.

PMID:
22208985
18.

Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.

Harms BD, Kearns JD, Su SV, Kohli N, Nielsen UB, Schoeberl B.

Methods Enzymol. 2012;502:67-87. doi: 10.1016/B978-0-12-416039-2.00004-5.

PMID:
22208982
19.

Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors.

Hendriks BS, Reynolds JG, Klinz SG, Geretti E, Lee H, Leonard SC, Gaddy DF, Espelin CW, Nielsen UB, Wickham TJ.

CPT Pharmacometrics Syst Pharmacol. 2012 Nov 21;1:e15. doi: 10.1038/psp.2012.16.

20.

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.

Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK.

Cancer Res. 2010 Mar 15;70(6):2485-94. doi: 10.1158/0008-5472.CAN-09-3145. Epub 2010 Mar 9.

21.

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB.

Sci Signal. 2009 Jun 30;2(77):ra31. doi: 10.1126/scisignal.2000352.

22.

Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data.

Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, Lauffenburger DA, Sorger PK.

Mol Syst Biol. 2009;5:239. doi: 10.1038/msb.2008.74. Epub 2009 Jan 20.

23.

A data-driven computational model of the ErbB receptor signaling network.

Schoeberl B, Pace E, Howard S, Garantcharova V, Kudla A, Sorger PK, Nielsen UB.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:53-4.

PMID:
17946779
24.

A novel assay for monitoring internalization of nanocarrier coupled antibodies.

Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD.

BMC Immunol. 2006 Oct 2;7:24.

25.

Systems biology and combination therapy in the quest for clinical efficacy.

Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK.

Nat Chem Biol. 2006 Sep;2(9):458-66.

PMID:
16921358
26.

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW.

Cancer Res. 2006 Jul 1;66(13):6732-40.

27.

The response of human epithelial cells to TNF involves an inducible autocrine cascade.

Janes KA, Gaudet S, Albeck JG, Nielsen UB, Lauffenburger DA, Sorger PK.

Cell. 2006 Mar 24;124(6):1225-39.

28.

Using computational modeling to drive the development of targeted therapeutics.

Nielsen UB, Schoeberl B.

IDrugs. 2005 Oct;8(10):822-6. Review.

PMID:
16254802
29.

Multiplexed sandwich assays in microarray format.

Nielsen UB, Geierstanger BH.

J Immunol Methods. 2004 Jul;290(1-2):107-20. Review.

PMID:
15261575
30.

Profiling receptor tyrosine kinase activation by using Ab microarrays.

Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK.

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9330-5. Epub 2003 Jul 22.

31.

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.

Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD.

Biochim Biophys Acta. 2002 Aug 19;1591(1-3):109-118.

32.

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.

Clin Cancer Res. 2002 Apr;8(4):1172-81.

33.

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC.

J Control Release. 2001 Jul 6;74(1-3):95-113.

PMID:
11489487
34.

Expression of single-chain Fv-Fc fusions in Pichia pastoris.

Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD.

J Immunol Methods. 2001 May 1;251(1-2):123-35.

PMID:
11292488
35.

Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.

Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC.

Biochem Biophys Res Commun. 2001 Jan 12;280(1):274-9.

PMID:
11162510
36.
37.

Selection of tumor-specific internalizing human antibodies from phage libraries.

Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD.

J Mol Biol. 2000 Sep 1;301(5):1149-61.

PMID:
10966812
38.

Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries.

Nielsen UB, Marks JD.

Pharm Sci Technolo Today. 2000 Aug;3(8):282-291.

PMID:
10916148
39.

Diverting a protein from its cellular location by intracellular antibodies. The case of p21Ras.

Lener M, Horn IR, Cardinale A, Messina S, Nielsen UB, Rybak SM, Hoogenboom HR, Cattaneo A, Biocca S.

Eur J Biochem. 2000 Feb;267(4):1196-205.

40.

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.

McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM.

Mol Immunol. 1999 May;36(7):433-45.

PMID:
10449096

Supplemental Content

Loading ...
Support Center